Spots Global Cancer Trial Database for Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
Official Title: Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
Study ID: NCT01436617
Interventions
Study Description
Brief Summary: The main objective of this study is to validate the utility of IgE anti-cetuximab in the treatment strategy to identify patients at risk for a severe allergic reaction to cetuximab (grade 3 or 4 of the classification of NCI) and thus reduce the incidence of severe reactions.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHU, Amiens, , France
Centre hospitalier, Bayeux, , France
CHU, Caen, , France
Centre François Baclesse, Caen, , France
Centre Georges-François Leclerc, Dijon, , France
Centre Oscar Lambret, Lille, , France
CHRU Lille, Lille, , France
CHU Charles Nicolle, Rouen, , France
Centre Henri Becquerel, Rouen, , France
Centre Paul Strauss, Strasbourg, , France
Contact Details
Name: GERVAIS Radj, MD
Affiliation: Centre François Baclesse
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
